Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Higher Gleason Score and ADT Efficacy: Examining the Link in Prostate Cancer

December 11, 2018
By John Schieszer
Article

Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.

Men with Gleason score 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score 8 disease. However, in individuals with Gleason score 8 prostate cancer, ADT is associated with an approximately 20% decrease in all-cause mortality. These are among the findings of a new analysis published in European Urology.

David Yang, MD, of Harvard Medical School and the Harvard Radiation Oncology Program in Boston, and colleagues conducted a retrospective study of more than 20,000 men from the National Cancer Database (NCDB). All individuals had localized or locally advanced, Gleason score 8–10 prostate cancer who received external beam radiation therapy (EBRT) between 2004 and 2012. In this cohort, 78% of men with Gleason score 8 disease (9,509 of 2,160) and 87% of men with Gleason score 9–10 disease (6,908 of 7,979) received ADT. The researchers aimed to examine the ADT and overall survival for those with a Gleason score of 8 (Grade Group 4) vs those with a Gleason score of 9–10 (Grade Group 5).

After conducing a multivariable analysis, Yang et al found that ADT was associated with a significant improvement in overall survival for patients with a Gleason score of 8 (adjusted hazard ratio [HR], 0.78), but not for those with a Gleason score of 9–10 (adjusted HR, 0.96). In addition, a higher Gleason score (8, 9, or 10) was associated with a decreasing benefit from ADT. However, the authors cautioned that the study is limited by the relatively short follow-up of a median of 4.0 years.

Based on the results of the study, intensification of therapy should be considered for prostate cancer patients with a Gleason score of 9–10, the authors concluded. They also encourage enrollment of such patients in clinical trials or potentially adding novel anti-androgens or docetaxel. Both of these therapies have been shown to be effective in castration-resistant and castration-sensitive settings, according to the authors.

Neil Desai, MD, who is an assistant professor of Radiation Oncology at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas, said this is a provocative study that contradicts the commonly held belief that ADT improves outcomes in high-grade prostate cancer, irrespective of specific grade. In an interview with Cancer Network, Desai said that these findings also speak to the long held concern that very high-grade Gleason score 9–10 patients on the verge of complete de-differentiation may no longer be androgen dependent for the prostate cancer progression, diminishing, if not eliminating, the benefit of ADT. However, multiple randomized controlled trials would be required to change clinical practice, he said.

Desai also cautioned about the caveats of a population database analysis like this one. “At best, this study should provoke post-hoc analysis of completed trials of high-grade prostate cancer undergoing ADT plus radiation therapy to ascertain whether this lack of benefit for Gleason 9–10 can be validated, or whether it is just a statistical anomaly of NCDB due to unaccounted for confounders, as has been seen in more cases than not with NCDB analyses,” Desai told Cancer Network.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Tim Cortese;Ariana Pelosci
May 14th 2025
Article

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Tim Cortese;Ariana Pelosci
May 14th 2025
Article

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.